SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
20.55
+0.10 (0.49%)
At close: Dec 5, 2025
80.90%
Market Cap1.10B
Revenue (ttm)n/a
Net Income (ttm)-106.28M
Shares Out53.33M
EPS (ttm)-2.21
PE Ration/a
Forward PE76.36
Dividendn/a
Ex-Dividend Daten/a
Volume41,783
Average Volume94,317
Open20.65
Previous Close20.45
Day's Range20.35 - 20.90
52-Week Range8.90 - 25.30
Beta1.14
RSI43.13
Earnings DateFeb 18, 2026

About SynAct Pharma AB

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.